SMMT Summit Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SMMT

Price (delayed)

$16.45

Market cap

$13.12B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.01

Enterprise value

$12.72B

?
Relative Growth: Rel. Growth: 7
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3
Highlights
SMMT's equity has surged by 143% year-on-year and by 15% since the previous quarter
The EPS has soared by 50% from the previous quarter
SMMT's quick ratio is up by 35% YoY but it is down by 7% QoQ
The net income has grown by 29% from the previous quarter but it has contracted by 15% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.summitplc.com
Peers: SRPT CHRS AMGN

Key stats

What are the main financial stats of SMMT

SMMT stock price

How has the Summit Therapeutics stock price performed over time
Intraday
-3.91%
1 week
-4.91%
1 month
25%
1 year
-14.1%
YTD
-5.95%
QTD
12.9%

Financial performance

How have Summit Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$874.84M
Net income
-$856.09M
Gross margin
N/A
Net margin
N/A
The net income has grown by 29% from the previous quarter but it has contracted by 15% YoY
The operating income has grown by 28% from the previous quarter but it has contracted by 15% YoY

Price vs fundamentals

How does SMMT's price correlate with its fundamentals

Growth

What is Summit Therapeutics's growth rate over time

Valuation

What is Summit Therapeutics stock price valuation
P/E
N/A
P/B
20.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 50% from the previous quarter
SMMT's equity has surged by 143% year-on-year and by 15% since the previous quarter
The P/B is 42% below the last 4 quarters average of 36.1 and 14% below the 5-year quarterly average of 24.6

Efficiency

How efficient is Summit Therapeutics business performance
SMMT's return on invested capital is up by 46% since the previous quarter and by 22% year-on-year
The ROA has grown by 42% from the previous quarter and by 22% YoY
The company's return on equity rose by 42% QoQ and by 19% YoY

Dividends

What is SMMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SMMT.

Financial health

How did Summit Therapeutics financials performed over time
SMMT's total assets has soared by 132% YoY and by 16% from the previous quarter
The total liabilities has surged by 89% year-on-year and by 20% since the previous quarter
The debt is 97% smaller than the equity
SMMT's equity has surged by 143% year-on-year and by 15% since the previous quarter
Summit Therapeutics's debt to equity has soared by 50% YoY but it has decreased by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.